Page 115 - 2023-05-中国全科医学
P. 115

·628·  http: //www.chinagp.net   E-mail: zgqkyx@chinagp.net.cn                    February  2023, Vol.26  No.5


               bmb.a071274.                                    [51]HUBER J C,SCHNEEBERGER C,TEMPFER C B. Genetic
           [46]AGUIRRE-URIZAR J M. Proliferative multifocal leukoplakia better   modelling of the estrogen metabolism as a risk factor of hormone-
               name that proliferative verrucous leukoplakia[J]. World J Surg   dependent disorders[J]. Maturitas,2002,42(1):1-12.
               Oncol,2011,9:122. DOI:10.1186/1477-7819-9-122.       DOI:10.1016/s0378-5122(02)00021-x.
           [47]KURIBAYASHI Y,TSUSHIMA F,MORITA K I,et al. Long-  [52]SUBA Z.Gender-related hormonal risk factors for oral cancer[J].
               term outcome of non-surgical treatment in patients with oral   Pathol  Oncol  Res,2007,13(3):195-202.  DOI:
               leukoplakia[J]. Oral Oncol,2015,51(11):1020-1025.    10.1007/BF02893499.
               DOI:10.1016/j.oraloncology.2015.09.004.         [53]LANGEVIN S M,GRANDIS J R,TAIOLI E. Female hormonal
           [48]GANDARA-VILA  P,PEREZ-SAYANS  M,SUAREZ-              and reproductive factors and head and neck squamous cell carcinoma
               PENARANDA J M,et al. Survival study of leukoplakia malignant   risk[J]. Cancer Lett,2011,310(2):216-221. DOI:
               transformation in a region of northern Spain[J]. Med Oral   10.1016/j.canlet.2011.07.007.
               Patol  Oral  Cir  Bucal,2018,23(4):e413-420.  DOI:  [54]MCGRATH  M,MICHAUD  D  S,VIVO  I  D.Hormonal  and
               10.4317/medoral.22326.                               reproductive factors and the risk of bladder cancer in women[J].
           [49]LIMA J S,CORREA L,KLINGBEIL M F,et al. c-Jun,        Am J Epidemiol,2006,163(3):236-244. DOI:10.1093/aje/
               pc-Jun,and p27 are differently expressed in oral leukoplakias   kwj028.
               in smokers and never-smokers[J]. Oral Surg Oral Med Oral   [55]PINDBORG J J,JOLST O,RENSTRUP G,et al. Studies in
               Pathol Oral Radiol,2016,121(1):73-80. DOI:10.1016/j.  oral leukoplakia:a preliminary report on the period pervalence of
               oooo.2015.09.003.                                    malignant transformation in leukoplakia based on a follow-up study
           [50]ZHANG X,KIM K Y,ZHENG Z,et al. Nomogram for risk     of 248 patients[J]. J Am Dent Assoc,1968,76(4):767-
               prediction of malignant transformation in oral leukoplakia patients   771. DOI:10.14219/jada.archive.1968.
               using combined biomarkers[J]. Oral Oncol,2017,72:132-      (收稿日期:2022-02-24;修回日期:2022-06-25)
               139. DOI:10.1016/j.oraloncology.2017.07.015.                                    (本文编辑:王俊懿)





           (上接第 606 页)                                              inhibitory concentrations of linezolid against multidrug-resistant
           [55]GUAN Y M,LIU Y. Meta-analysis on effectiveness and safety   tuberculosis strains[J]. Eur Respir J,2015,45(1):287-
               of moxifloxacin in treatment of multidrug resistant tuberculosis   289. DOI:10.1183/09031936.00135014.
               in adults[J]. Medicine,2020,99(25):e20648. DOI:  [61]LEE M,CHO S N,BARRY C E 3rd,et al. Linezolid for XDR-
               10.1097/MD.0000000000020648.                         TB—final study outcomes[J]. N Engl J Med,2015,373(3):
           [56]MARQUES M G,CANCELLI C H B,FERNANDES C M S,et al.    290-291. DOI:10.1056/NEJMc1500286.
               Effect of a constant rate infusion of remifentanil hydrochloride on left   [62]PATEL P D,AFSHAR H,BIRNBAUM Y. Levofloxacin-induced
               ventricular systolic and diastolic function in propofol-anesthetized   torsades de pointes[J]. Tex Heart Inst J,2010,37(2):216-
               dogs[J]. Am J Vet Res,2018,79(12):1261-1267. DOI:    217.
               10.2460/ajvr.79.12.1261.                        [63]ALTIN T,OZCAN O,TURHAN S,et al. Torsade de pointes
           [57]王述蓉,冯申奎,黄毅岚,等 . 莫西沙星与左氧氟沙星治疗耐                        associated with moxifloxacin:a rare but potentially fatal adverse
               多药肺结核的系统评价[J]. 中华医院感染学杂志,2015,25                     event[J]. Can J Cardiol,2007,23(11):907-908. DOI:
               (15):3446-3449.                                      10.1016/s0828-282x(07)70850-4.
           [58]MENDES R E,DESHPANDE L M,JONES R N. Linezolid   [64]NOEL G J,NATARAJAN J,CHIEN S,et al. Effects of three
               update:stable in vitro activity following more than a decade of   fluoroquinolones on QT interval in healthy adults after single
               clinical use and summary of associated resistance mechanisms[J].   doses[J]. Clin Pharmacol Ther,2003,73(4):292-303.
               Drug Resist Updat,2014,17(1/2):1-12. DOI:10.1016/j.  DOI:10.1016/s0009-9236(03)00009-2.
               drup.2014.04.002.                               [65]ANGER H A,DWORKIN F,SHARMA S,et al. Linezolid use
           [59]MENDES R E,FARRELL D J,SADER H S,et al. Oritavancin   for treatment of multidrug-resistant and extensively drug-resistant
               activity tested against molecularly characterized staphylococci   tuberculosis,New York City,2000-06[J]. J Antimicrob
               and enterococci displaying elevated linezolid MIC results[J].   Chemother,2010,65(4):775-783. DOI:10.1093/jac/
               Antimicrob Agents Chemother,2016,60(6):3817-3820.    dkq017.
               DOI:10.1128/AAC.00281-16.                                  (收稿日期:2022-04-01;修回日期:2022-08-02)
           [60]SOTGIU G,CENTIS R,D'AMBROSIO L,et al. Low minimal                               (本文编辑:贾萌萌)
   110   111   112   113   114   115   116   117   118   119   120